Compare Gilead Sciences, Inc. (GILD) vs Monster Beverage Corp (MNST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Monster Beverage Corp — how do they compare? Gilead Sciences, Inc. trades at $135.95 (market cap $168.35B), while Monster Beverage Corp trades at $45.5 (market cap $89.20B). The key difference: Gilead Sciences, Inc. is the larger of the two by market cap, and Gilead Sciences, Inc. pays a 2.42% dividend while Monster Beverage Corp pays none. Which is the better fit depends on your goals.
| GILD | MNST | |
|---|---|---|
Market Cap | $168.35B | $89.20B |
Sector | Health | Consumer Staples |
52-Week High | $155.80 | $49.97 |
52-Week Low | $110.56 | $30.86 |
Enterprise Value | $191.42B | $87.49B |
Dividend Yield | 2.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.06, down slightly by 0.11% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 revenue growth of 8% year-over-year, beating estimates, though a net loss of $6.75 per share resulted from acquisition-related costs. Analyst consensus is strongly bullish with a $151.22 price target, and recent news highlights robust HIV drug sales and pipeline progress.
The outlook for GILD is positive, driven by raised 2026 guidance and HIV franchise strength, but risks include patent cliffs by the mid-2030s and integration challenges from acquisitions. Investors should weigh the high valuation multiples against growth potential, with the stock offering upside if execution continues to exceed expectations.
Monster Beverage (MNST) trades at $45.69, up 1.13% today. The stock shows strong fundamentals with Q2 2026 EPS of $0.60 beating estimates, driven by 20% revenue growth and a 23.08% net income margin. A 2-for-1 stock split occurred on August 11, 2026. However, technical indicators signal a bearish trend, with the current price below key resistance levels. Analyst consensus is bullish with a $51.14 price target, but high valuation ratios like a P/E of 42.16 pose risks.
Outlook: MNST's international expansion and earnings beats support growth, but stretched valuations and bearish technicals suggest near-term volatility. Investment opportunity lies in sustained profit margins, while risks include competitive pressures and premium pricing sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →
